American Century Companies Inc. cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 393,922 shares of the life sciences company’s stock after selling 52,381 shares during the quarter. American Century Companies Inc. owned 0.27% of Illumina worth $118,149,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Massmutual Trust Co. FSB ADV increased its position in shares of Illumina by 83.0% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 39 shares during the last quarter. Proficio Capital Partners LLC lifted its stake in Illumina by 61.7% in the fourth quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock valued at $29,000 after buying an additional 37 shares during the last quarter. Lake Point Wealth Management purchased a new stake in Illumina in the fourth quarter valued at approximately $30,000. Moody National Bank Trust Division purchased a new stake in Illumina in the fourth quarter valued at approximately $31,000. Finally, Virtus ETF Advisers LLC purchased a new stake in Illumina in the fourth quarter valued at approximately $31,000. 90.46% of the stock is currently owned by institutional investors.
In other news, SVP Aimee L. Hoyt sold 298 shares of the company’s stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $304.63, for a total value of $90,779.74. Following the sale, the senior vice president now directly owns 2,297 shares in the company, valued at $699,735.11. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Charles Dadswell sold 124 shares of the stock in a transaction dated Friday, February 1st. The stock was sold at an average price of $280.11, for a total value of $34,733.64. Following the transaction, the senior vice president now owns 6,879 shares in the company, valued at $1,926,876.69. The disclosure for this sale can be found here. Insiders sold 31,526 shares of company stock worth $9,602,911 over the last 90 days. Company insiders own 0.38% of the company’s stock.
Shares of NASDAQ:ILMN traded down $7.54 on Wednesday, hitting $314.52. The company had a trading volume of 901,369 shares, compared to its average volume of 963,003. The company has a quick ratio of 2.27, a current ratio of 2.49 and a debt-to-equity ratio of 0.23. Illumina, Inc. has a 52-week low of $226.62 and a 52-week high of $372.61. The company has a market capitalization of $47.31 billion, a P/E ratio of 54.99, a P/E/G ratio of 2.27 and a beta of 1.17.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.04). Illumina had a net margin of 24.79% and a return on equity of 24.51%. The company had revenue of $867.00 million during the quarter, compared to analysts’ expectations of $865.33 million. During the same quarter in the prior year, the company earned $1.44 earnings per share. The firm’s revenue was up 11.4% compared to the same quarter last year. On average, sell-side analysts anticipate that Illumina, Inc. will post 6.53 earnings per share for the current year.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Recommended Story: Do back-end load funds outperform no-load funds?
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.